用于非瓣膜性心房颤动患者的新型口服抗凝剂。

New oral anticoagulants for patients with nonvalvular atrial fibrillation.

作者信息

Holden Amber, Azimi Nassir, Forest Christopher P

机构信息

Amber Holden practices at Rancho Family Medical Group in Temecula, Calif. Nassir Azimi is chair of medicine and co-chair of the endovascular committee at Sharp Grossmont Hospital in La Mesa, Calif., a partner in the La Mesa Cardiac Center, a member of the San Diego County Cardiovascular Advisory Committee, and a clinical faculty member at Midwestern School of Medicine in Glendale, Ariz. Christopher P. Forest is an assistant professor of clinical family medicine and director of research at the University of Southern California's Keck School of Medicine and practices urgent care and family medicine in Los Angeles, Calif. Dr. Azimi discloses that he receives payment to speak about rivaroxaban and dabigatran. The other authors have disclosed no potential conflicts of interest, financial or otherwise.

出版信息

JAAPA. 2015 Nov;28(11):28-34. doi: 10.1097/01.JAA.0000471615.92278.1c.

DOI:10.1097/01.JAA.0000471615.92278.1c

PMID:26501575

Abstract

Four new oral anticoagulants have been approved for reducing stroke risk in patients with nonvalvular atrial fibrillation. Compared with warfarin, these agents offer a more predictable dose response with fewer food and drug interactions and no regular blood monitoring, although some of the drugs have an increased risk of major gastrointestinal bleeding. This article reviews the new drugs.

摘要

四种新型口服抗凝药已被批准用于降低非瓣膜性心房颤动患者的中风风险。与华法林相比，这些药物的剂量反应更可预测，食物和药物相互作用更少，且无需定期进行血液监测，不过有些药物发生严重胃肠道出血的风险增加。本文对这些新药进行综述。